Injectable semaglutide is administered once weekly on the same day. Severe persistent abdominal pain, sometimes radiating to the back, can indicate acute pancreatitis and requires prompt evaluation. A neck mass, trouble swallowing, shortness of breath, or persistent hoarseness can indicate a thyroid tumor. Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
In-depth explanation
Clinical reasoning
Semaglutide is a once-weekly GLP-1 receptor agonist. High-priority teaching addresses pancreatitis symptoms and the boxed thyroid C-cell tumor warning.
Decision rule
Keep a consistent weekly schedule, report persistent severe abdominal pain immediately, and screen for personal or family medullary thyroid carcinoma or MEN 2 before treatment.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.